title: Management of spasticity in progressive multiple sclerosis: efficacy of repeated intrathecal triamcinolone acetonide administration.
abstract: Multiple sclerosis (MS) as a chronic disease presents a vast variability of neurological symptoms. Spasticity is one of the most common symptoms. The principle indication to treat spasticity is disability or handicap of capabilities. All pharmacological methods are attributed to a basic physical management. Different effective treatment schemes have been established. Nevertheless the value of intrathecal triamcinolone acetonid (TCA) in MS is still a controversial issue. Bearing in mind that only limited data are available and due to its invasive application form repeated TCA administration can be recommended as one therapy option in MS with a progressive clinical course and predominantly spinal symptoms.
authors.affiliation: Department of Neurology, University of Rostock, Gehlsheimer Str. 20, D - 18147 Rostock, Germany. mazen.abu-mugheisib@med.uni-rostock.de
authors.forename: Mazen
authors.initials: M
authors.lastname: Abu-Mugheisib
authors.forename: Reiner
authors.initials: R
authors.lastname: Benecke
authors.forename: Uwe K
authors.initials: UK
authors.lastname: Zettl
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004185:Disability Evaluation; D018450:Disease Progression; D004334:Drug Administration Schedule; D006801:Humans; D007278:Injections, Spinal; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy* / Q000503:physiopathology; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D014222:Triamcinolone Acetonide